Document is current
Any future updates will be listed below
-
Authors
Aiyegbusi, Olalekan Lee https://orcid.org/0000-0001-9122-8251
McMullan, Christel
Hughes, Sarah E. https://orcid.org/0000-0001-5656-1198
Turner, Grace M.
Subramanian, Anuradhaa https://orcid.org/0000-0001-8875-7363
Hotham, Richard
Davies, Elin Haf
Frost, Chris
Alder, Yvonne
Agyen, Lisa
Buckland, Lewis
Camaradou, Jennifer
Chong, Amy
Jeyes, Felicity
Kumar, Sumita
Matthews, Karen L.
Moore, Patricia
Ormerod, Jane
Price, Gary
Saint-Cricq, Michael
Stanton, David
Walker, Anita
Haroon, Shamil https://orcid.org/0000-0002-0096-1413
Denniston, Alastair K. https://orcid.org/0000-0001-7849-0087
Calvert, Melanie J. https://orcid.org/0000-0002-1856-837X
,
Brown, Kirsty
Singh Chandan, Joht
Gkoutos, Georgios V.
Jackson, Louise J.
Lord, Janet M.
Marshall, Tom
Marwaha, Steven
Myles, Puja
Nirantharakumar, Krishnarajah
Rivera, Samantha Cruz
Sapey, Elizabeth
Simms-Williams, Nikita
Williams, Tim
Wraith, David C.
- License Information
-
More Information
Article History
Received: 1 February 2023
Accepted: 7 June 2023
First Online: 20 July 2023
Competing interests
: O.L.A. declares personal fees from Gilead Sciences, Merck and GlaxoSmithKline outside the submitted work and receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Applied Research Collaboration (ARC), West Midlands, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UKRI), Gilead Sciences, Merck, Anthony Nolan and Sarcoma UK. S.E.H. receives funding from the NIHR ARC, West Midlands, NIHR BTRU in Precision Transplant and Cellular Therapeutics at the University of Birmingham and Anthony Nolan. S.E.H. declares personal fees from Cochlear and Aparito outside the submitted work. C.M. receives funding from the NIHR Surgical Reconstruction and Microbiology Research Centre, the NIHR BTRU in Precision Transplant and Cellular Therapeutics, Innovate UK and Anthony Nolan, and has received personal fees from Aparito outside the submitted work. K.L.M. is a Trustee and volunteer at Long COVID SOS. K.L.M. is on the Long COVID Advisory Board for Dysautonomia International and is employed by the NIHR. J.C. receives funding from NIHR on PPI from a study at UCL (NIHR132914) and a study at University Hospitals Bristol (NIHR203304). J.C. is a lay member on the NICE COVID-19 expert panel and a citizen partner on the COVID END Evidence Synthesis Global Horizon Scanning panel. J.C. declares personal fees from MEDABLE, GlaxoSmithKline and Roche Canada outside of the submitted work. S.H. receives funding from NIHR and UKRI. M.J.C. received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute outside the submitted work. In addition, a family member owns shares in GSK. M.C. receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR BTRU in Precision Transplant and Cellular Therapeutics, and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UKRI), Macmillan Cancer Support, European Regional Development Fund—Demand Hub, SPINE UK, UKRI, UCB Pharma, GSK, Anthony Nolan and Gilead Sciences. All other authors declare no competing interests. This study was approved by the Health Research Authority and the West Midlands Solihull-Research Ethics Committee (IRAS project ID: 296374; REC reference: 21/WM/0203).
